Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 5:35 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 2,694 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Autologous hematopoietic stem cell transplantation Clear all
Active, not recruiting Phase 2 Interventional

Randomized Double-Blind Placebo-Controlled Adaptive Design Trial Of Intrathecally Administered Autologous Mesenchymal Stem Cells In Multiple System Atrophy

NCT05167721
View directory record Official record
Conditions
Multiple System Atrophy
Interventions
Autologous Mesenchymal Stem Cells, Placebo
Biological · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
30 Years to 70 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 15, 2026, 5:35 AM EDT
Terminated Phase 1 Interventional

Autologous Stem Cells for Spinal Cord Injury (SCI) in Children

NCT01328860
View directory record Official record
Conditions
Spinal Cord Injury
Interventions
bone marrow progenitor cells (BMPC) autologous transplantation
Biological
Lead sponsor
Aryn Knight
Other
Eligibility
1 Year to 15 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 20, 2024 · Synced Oct 15, 2026, 5:35 AM EDT
Terminated Phase 1 Interventional

Tumor Cell Vaccines and ISCOMATRIX With Chemotherapy After Tumor Removal

NCT01341496
View directory record Official record
Conditions
Sarcoma, Melanoma, Epithelial Malignancies, Pleural Malignancy
Interventions
Epigenetically Modified Autologous Tumor, Cyclophosphamide, Celecoxib
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 5, 2018 · Synced Oct 15, 2026, 5:35 AM EDT
Completed Phase 1 Interventional Results available

Vaccination With Autologous Breast Cancer Cells Engineered to Secrete Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Metastatic Breast Cancer Patients

NCT00317603
View directory record Official record
Conditions
Breast Cancer
Interventions
Autologous, Lethally Irradiated Breast Cancer Cells
Biological
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2021
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 1, 2022 · Synced Oct 15, 2026, 5:35 AM EDT
Completed Not applicable Interventional

Mixed Chimera Allogeneic Transplantation From Matched Unrelated Donors For The Treatment Of Multiple Myeloma

NCT00185653
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Autologous followed by non-myeloablative allogeneic transplantation
Procedure
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2008
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Feb 14, 2011 · Synced Oct 15, 2026, 5:35 AM EDT
Recruiting Phase 2 Interventional

REgulatory T Cell Therapy to Achieve Immunosuppression REduction

NCT06552169
View directory record Official record
Conditions
Kidney Transplantation
Interventions
Arm 1: SOC (mTOR + CNI), Arm 2A: TRACT/MONO mTOR, Arm 2B: TRACT/MONO CNI
Drug · Biological
Lead sponsor
Singulera Therapeutics Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
3
States / cities
Phoenix, Arizona • Chicago, Illinois • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Oct 15, 2026, 5:35 AM EDT
Active, not recruiting Not applicable Interventional

P-15L Bone Graft in Transforaminal Lumbar Interbody Fusion With Instrumentation

NCT03438747
View directory record Official record
Conditions
Degenerative Disc Disease
Interventions
P-15L Bone Graft, Local autologous bone in a TLIF with Instrumentation
Device · Other
Lead sponsor
CeraPedics, Inc
Industry
Eligibility
22 Years to 80 Years
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
34
States / cities
Birmingham, Alabama • Glendale, California • Los Angeles, California + 27 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2025 · Synced Oct 15, 2026, 5:35 AM EDT
Recruiting No phase listed Observational

Ovarian Tissue Cryopreservation for Fertility Preservation

NCT05875155
View directory record Official record
Conditions
Cancer, Autoimmune Diseases
Interventions
Infectious Disease Labwork, Fertility-Based Labwork
Diagnostic Test
Lead sponsor
University of Pittsburgh
Other
Eligibility
Up to 39 Years · Female only
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2031
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Oct 15, 2026, 5:35 AM EDT
Completed Phase 2 Interventional

Use of Ixmyelocel-T (Formerly Cardiac Repair Cell [CRC] Treatment) in Patients With Heart Failure Due to Dilated Cardiomyopathy (IMPACT-DCM)

NCT00765518
View directory record Official record
Conditions
Dilated Cardiomyopathy
Interventions
Ixmyelocel-T, Standard of Care
Biological · Other
Lead sponsor
Vericel Corporation
Industry
Eligibility
18 Years to 86 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
5
States / cities
Atlanta, Georgia • Cleveland, Ohio • Dallas, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated May 27, 2021 · Synced Oct 15, 2026, 5:35 AM EDT
Completed Phase 1 Interventional

N2007-03: Vorinostat and 131-I MIBG in Treating Patients With Resistant or Relapsed Neuroblastoma

NCT01019850
View directory record Official record
Conditions
Neuroblastoma
Interventions
Vorinostat, 131- I Metaiodobenzylguanidine, Peripheral Blood Stem Cell Infusion, Filgrastim
Drug · Radiation · Procedure
Lead sponsor
New Approaches to Neuroblastoma Therapy Consortium
Other
Eligibility
2 Years to 30 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
12
States / cities
Los Angeles, California • Palo Alto, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2023 · Synced Oct 15, 2026, 5:35 AM EDT
Terminated Phase 1 Interventional

Ex Vivo-Activated Lymph Node Lymphocytes in Treating Patients With Stage IIIC-IV Melanoma

NCT02327390
View directory record Official record
Conditions
Stage IIIC Skin Melanoma, Stage IV Melanoma
Interventions
lymph node, X-ACT
Procedure · Biological
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 6, 2018 · Synced Oct 15, 2026, 5:35 AM EDT
Withdrawn Early Phase 1 Interventional Accepts healthy volunteers

Mesenchymal Stem Cells for Lumbar Degenerative Disc Disease

NCT03692221
View directory record Official record
Conditions
Disc Degeneration
Interventions
MSC Treatment group 1 (low dose), MSC Treatment group 2 (high dose), Healthy Control (no treatment)
Drug · Other
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 5, 2022 · Synced Oct 15, 2026, 5:35 AM EDT
Recruiting Phase 1Phase 2 Interventional

Autologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for Pediatric B-ALL (huCART19 Prodigy)

NCT05480449
View directory record Official record
Conditions
B Cell Acute Lymphoblastic Leukemia (B-ALL), B Lineage Lymphoblastic Lymphoma
Interventions
Autologous Humanized CD19-Directed Chimeric Antigen Receptor T-Cells (huCART19)
Biological
Lead sponsor
Stephan Grupp MD PhD
Other
Eligibility
0 Years to 29 Years
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Oct 15, 2026, 5:35 AM EDT
Completed Phase 2 Interventional

Vaccine Therapy in Treating Patients With Metastatic Melanoma

NCT00334776
View directory record Official record
Conditions
Intraocular Melanoma, Melanoma (Skin)
Interventions
MART-1 antigen, gp100:209-217(210M) peptide vaccine, therapeutic autologous dendritic cells, tyrosinase peptide
Biological
Lead sponsor
University of Southern California
Other
Eligibility
16 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
2
States / cities
Los Angeles, California • Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 21, 2014 · Synced Oct 15, 2026, 5:35 AM EDT
Not yet recruiting Phase 2 Interventional

NANT 2021-02: Randomized MIBG With Vorinostat/Dinutuximab/Vorinostat + Dinutuximab

NCT07261241
View directory record Official record
Conditions
Neuroblastoma
Interventions
Radiation: 131I-MIBG, Dinutuximab, Vorinostat
Drug
Lead sponsor
New Approaches to Neuroblastoma Therapy Consortium
Other
Eligibility
1 Year to 30 Years
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
13
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 15, 2026, 5:35 AM EDT
Active, not recruiting Phase 1 Interventional

Study of AIC100 CAR T Cells in Relapsed/Refractory Thyroid Cancer

NCT04420754
View directory record Official record
Conditions
Anaplastic Thyroid Cancer, Relapsed/Refractory Poorly Differentiated Thyroid Cancer
Interventions
AIC100 CAR T Cells
Biological
Lead sponsor
AffyImmune Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
4
States / cities
Duarte, California • Chicago, Illinois • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2025 · Synced Oct 15, 2026, 5:35 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

AuraClens™ System in Processing of Lipoaspirate for Autologous Fat Grafting to the Breast

NCT05258305
View directory record Official record
Conditions
Breast Fat Grafting Retention
Interventions
AuraGen 1-2-3 with AuraClens
Device
Lead sponsor
Tiger Biosciences, LLC.
Industry
Eligibility
22 Years to 65 Years · Female only
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
14
States / cities
Scottsdale, Arizona • Beverly Hills, California • Miami, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 15, 2026, 5:35 AM EDT
Completed Not applicable Interventional

Acute Normovolemic Hemodilution in Patients Undergoing Cytoreductive Surgery for Advanced Ovarian Cancer

NCT01442051
View directory record Official record
Conditions
Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
Interventions
Acute Normovolemic Hemodilution
Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 69 Years · Female only
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
4
States / cities
Basking Ridge, New Jersey • Commack, New York • Harrison, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2019 · Synced Oct 15, 2026, 5:35 AM EDT
Not listed Phase 1 Interventional

Autologous CD34+ Stem Cell Injection for Severe Intermittent Claudication (Leg Pain)

NCT00311805
View directory record Official record
Conditions
Peripheral Artery Disease, Severe Intermittent Claudication
Interventions
Autologous Stem Cells (CD34+)
Biological
Lead sponsor
Losordo, Douglas, M.D.
Individual
Eligibility
21 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
2
States / cities
Birmingham, Alabama • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 31, 2015 · Synced Oct 15, 2026, 5:35 AM EDT
Completed Phase 1 Interventional

BG & TMZ Therapy of Glioblastoma Multiforme

NCT01269424
View directory record Official record
Conditions
Glioblastoma Multiforme
Interventions
MGMTP140K-encoding retroviral vector, O6-benzylguanine, temozolomide, laboratory biomarker analysis, autologous hematopoietic stem cell transplantation, in vitro-treated peripheral blood stem cell transplantation, radiation therapy
Biological · Drug · Other + 2 more
Lead sponsor
Stanton Gerson MD
Other
Eligibility
18 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2022
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 2, 2023 · Synced Oct 15, 2026, 5:35 AM EDT
Recruiting Phase 1 Interventional

Anterior Cruciate Ligament (ACL) Reconstruction With Autologous Fat Pad Derived Mesenchymal Stem Cells

NCT06798623
View directory record Official record
Conditions
Anterior Cruciate Ligament Reconstruction
Interventions
Autologous Mesenchymal Stromal Cells
Biological
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Oct 15, 2026, 5:35 AM EDT
Terminated Phase 1 Interventional

Safety and Efficacy of Adipose Derived Stem Cells in Refractory Rheumatoid Arthritis, Systemic Lupus Erythematosus or Sharp's Syndrome

NCT02741362
View directory record Official record
Conditions
Systemic Lupus Erythematosus, Rheumatoid Arthritis, Sharp's Syndrome
Interventions
Intravenous injection of Stromal Vascular Fraction Cells (SVF) containing ADSCs, Lipoaspiration
Other
Lead sponsor
Arkansas Heart Hospital
Other
Eligibility
18 Years to 99 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Mar 3, 2017 · Synced Oct 15, 2026, 5:35 AM EDT